Month: March 2023
H.Pylori infection and Genetics of Gastric Cancer
Helicobacter pylori infection can increase the chances or risk of getting stomach cancer. A research study published in NEJM in March 2023 looked at how…
New FDA approval for Tucatinib (brand name Tukysa) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer: MOUNTAINEER study
The MOUNTAINEER trial was a multicenter, open-label study that focused on patients with unresectable or metastatic colorectal cancer who had HER2-positive and RAS wild-type tumors,…
A new treatment Retifanlimab-dlwr (Zynyz) received FDA accelerated approval for Merkel cell carcinoma (a skin cancer type)
Merkel cell carcinoma (MCC) is a type of skin cancer that can be challenging to treat, particularly in its advanced stages. However, a new drug…
Trifluridine/tipiracil (Lonsurf) plus bevacizumab (Avastin) showing response in overall survival for refractory metastatic colorectal cancer: The phase 3, randomized SUNLIGHT study
Metastatic colorectal cancer (mCRC) is a significant cause of cancer-related mortality worldwide. Despite the availability of several treatment options, refractory mCRC remains a challenging clinical…
Treatment of HepatoCellular Cancer (HCC) in advanced and metastatic disease
Hepatocellular carcinoma (HCC) is a type of liver cancer that often develops in individuals with chronic liver disease. Treatment options for HCC depend on the…
Keytruda (Pembrolizumab) role as adjuvant immunotherapy in Kidney Cancer after Nephrectomy
Immunotherapy role (as adjuvant) in Kidney cancer (Renal Cell Cancer) after nephrectomy is evolving. Kidney cancer, also known as renal cell carcinoma, is one of…